
Sign up to save your podcasts
Or
What are the early diagnostic stages of Alzheimer’s disease? What sort of brain changes can occur up to 20 years prior to symptoms of Alzheimer’s disease?
In this episode, Dr. Danielle Goldfarb addresses these questions and much more! She shares the most current research on dementia and geriatrics relevant to clinical practice. She also shares resources for early diagnosis of dementia and treating mental health in geriatrics.
Dr. Danielle Goldfarb is an Assistant Professor of Neurology and Psychiatry at the University of Arizona and a dual board-certified neurologist and psychiatrist at the Banner Sun Health Research Institute and Cleo Roberts Memory Center in Sun City, AZ. Dr. Goldfarb cares for patients and families with Alzheimer’s disease and related dementias (ADRD). She leads several Alzheimer’s clinical trials and is involved in research efforts to explore the neuropathologic substrates of early neuropsychiatric symptoms in ADRD, to improve the safety and efficiency of the collection of cerebrospinal fluid biomarkers in older adults, and to expand access to ADRD care and research by underserved communities.
4.5
115115 ratings
What are the early diagnostic stages of Alzheimer’s disease? What sort of brain changes can occur up to 20 years prior to symptoms of Alzheimer’s disease?
In this episode, Dr. Danielle Goldfarb addresses these questions and much more! She shares the most current research on dementia and geriatrics relevant to clinical practice. She also shares resources for early diagnosis of dementia and treating mental health in geriatrics.
Dr. Danielle Goldfarb is an Assistant Professor of Neurology and Psychiatry at the University of Arizona and a dual board-certified neurologist and psychiatrist at the Banner Sun Health Research Institute and Cleo Roberts Memory Center in Sun City, AZ. Dr. Goldfarb cares for patients and families with Alzheimer’s disease and related dementias (ADRD). She leads several Alzheimer’s clinical trials and is involved in research efforts to explore the neuropathologic substrates of early neuropsychiatric symptoms in ADRD, to improve the safety and efficiency of the collection of cerebrospinal fluid biomarkers in older adults, and to expand access to ADRD care and research by underserved communities.
1,304 Listeners
601 Listeners
264 Listeners
3,317 Listeners
147 Listeners
1,299 Listeners
694 Listeners
283 Listeners
345 Listeners
563 Listeners
446 Listeners
675 Listeners
113 Listeners
153 Listeners
99 Listeners